Arkenlight’s core innovation is diamond-based betavoltaic battery technology that converts energy from radioactive isotopes like carbon-14 and tritium into electricity by capturing beta particles emitted during radioactive decay and converting them into electrical energy. This environmentally friendly process produces no harmful emissions. Their batteries deliver continuous power for decades or millennia, with tritium-based betalight batteries already commercially available and carbon-14 diamond batteries in advanced development.
Arkenlight’s flagship product is the Diamond Battery, designed to provide continuous power for thousands of years and suitable for extreme environments, industrial sensors, medical implants, and satellites. The commercially available tritium-based betalight batteries offer higher efficiency than competitors. Carbon-14 diamond batteries are still under development, aiming to repurpose nuclear waste into sustainable power sources.
Arkenlight has successfully grown diamonds using carbon-14 bringing carbon-14 diamond batteries closer to commercialization (TRL 4). They have collaborated with Axorus to develop artificial neurons powered by diamond batteries targeting retinal implants for Age-related Macular Degeneration patients. The company also partners with the UK Atomic Energy Authority and other entities to refine technology and explore applications in industrial IoT, space exploration, and luxury watches.
Key investors include the University of Bristol holding approximately 19.0%. Morgan Jay Boardman was a significant shareholder but resigned as a director in 2024. The founding team, led by Professors Neil Fox and Tom Scott, remains active in the company.
